Specific Cytotoxicity of Targeted 177Lu and 212Pb-Based Radiopharmaceuticals

Панкратов, А. А.; Немцова, Е. Р.; Plyutinskaya, A. D.; Воронцова, М. С.; Chuvilin, D. Yu.; Egorova, Bayirta V.; Kokov, Konstantin; Deyev, Sergey M.; Лебеденко, Е. Н.; Прошкина, Г. М.; Shulga, A. A.; Golovachenko, V.; Shegai, P. V.; Каприн, А. Д.

doi:10.1007/s10517-021-05283-4

Cited by 2 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another concept of such 212 Pb production for nuclear medicine investigations was implemented in [40] and used in [41][42][43]. A 212 Pb generator with 228 Th as a parent isotope was designed.…”

Section: Primary Production Techniques From the Beginning To The Presentmentioning

confidence: 99%

212Pb: Production Approaches and Targeted Therapy Applications

et al. 2022

View full text Add to dashboard Cite

Over the last decade, targeted alpha therapy has demonstrated its high effectiveness in treating various oncological diseases. Lead-212, with a convenient half-life of 10.64 h, and daughter alpha-emitter short-lived 212Bi (T1/2 = 1 h), provides the possibility for the synthesis and purification of complex radiopharmaceuticals with minimum loss of radioactivity during preparation. As a benefit for clinical implementation, it can be milked from a radionuclide generator in different ways. The main approaches applied for these purposes are considered and described in this review, including chromatographic, solution, and other techniques to isolate 212Pb from its parent radionuclide. Furthermore, molecules used for lead’s binding and radiochemical features of preparation and stability of compounds labeled with 212Pb are discussed. The results of preclinical studies with an estimation of therapeutic and tolerant doses as well as recently initiated clinical trials of targeted radiopharmaceuticals are presented.

show abstract

Section: Primary Production Techniques From the Beginning To The Presentmentioning

confidence: 99%

212Pb: Production Approaches and Targeted Therapy Applications

et al. 2022

View full text Add to dashboard Cite

show abstract

Targeted Nuclear Medicine. Achievements, Challenges and Prospects

Kovalchuk,

Deyev,

Sergunova

2023

Nanotechnol Russia

View full text Add to dashboard Cite

The path of the development of nuclear medicine at the international level and that in Russia is presented. Significant achievements in the development and establishment of nuclear-physics technologies and the development of targeted radiopharmaceuticals (RPs) are presented. The main directions of targeted nuclear medicine are shown. The physical–chemical aspects of the synthesis of radiopharmaceuticals are considered, and the advantages and specificity of vector carrier molecules are shown.

show abstract

Specific Cytotoxicity of Targeted 177Lu and 212Pb-Based Radiopharmaceuticals

Cited by 2 publications

References 13 publications

212Pb: Production Approaches and Targeted Therapy Applications

212Pb: Production Approaches and Targeted Therapy Applications

Targeted Nuclear Medicine. Achievements, Challenges and Prospects

Contact Info

Product

Resources

About